Publisher
Springer International Publishing
Reference43 articles.
1. Leblanc H, Lachelin GC, Abu-Fadil S, Yen SS. Effects of dopamine infusion on pituitary hormone secretion in humans. J Clin Endocrinol Metab. 1976;43:668–74.
2. Jacobs LS, Snyder PJ, Wilber JF, Utiger RD, Daughaday WH. Increased serum prolactin after administration of synthetic thyrotropin releasing hormone (TRH) in man. J Clin Endocrinol Metab. 1971;33:996–8.
3. Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, Schoenfelder JR, Klibanski A. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab. 1996;81:2338–43.
4. Ali S, Miller KK, Freudenreich O. Management of psychosis associated with a prolactinoma: case report and review of the literature. Psychosomatics. 2010;51:370–6.
5. DA agonists—ergot derivatives: cabergoline: management of Parkinson’s disease. Mov Disord. 2002;17 Suppl 4:S68–71.